AERI - Aerie Pharmaceuticals, Inc.
| Previous close | 20.51 |
| Open | 20.59 |
| Bid | 19.69 x 1200 |
| Ask | 19.71 x 800 |
| Day's range | 19.52 - 20.70 |
| 52-week range | 17.51 - 60.04 |
| Volume | 797,951 |
| Avg. volume | 1,283,673 |
| Market cap | 880.804M |
| Beta (3Y monthly) | 0.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.17 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 63.11 |
- Business Wire
Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer, reporting to John LaRocca, Aerie’s General Counsel. Ms. Davis will oversee the world wide compliance and data privacy functions for the Company.
- Business Wire
Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present in a fireside discussion at the 2019 Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2, 2019 at 3:35 p.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.
- Zacks
Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa
The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
- Business Wire
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%. The recommended indication is the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension. The CHMP positive opinion is a scientific recommendation for marketing authorisation referred to the European Commission for a final decision on the Company’s MAA.
- Simply Wall St.
Will Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Need To Raise More Money?
As the US$994m market cap Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released another year of negative earnings...
- Business Wire
Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its Athlone Ireland Facility
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the submission of a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA). If approved, the PAS will permit production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for sale in the United States in Aerie’s new manufacturing plant in Athlone, Ireland.
- Business Wire
Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aerie’s 1.50% Convertible Senior Notes Due 2024
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the initial purchasers of the previously announced offering of Aerie’s 1.50% Convertible Senior Notes due 2024 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to fully exercise their option to purchase an additional $41.25 million aggregate principal amount of the notes. The settlement of the sale of additional notes pursuant to the option is expected to occur on September 12, 2019, subject to customary closing conditions.
- Zacks
Aerie (AERI) Down 19.7% Since Last Earnings Report: Can It Rebound?
Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that it has priced $275 million aggregate principal amount of its 1.50% convertible senior notes due 2024 (the “notes”). The offering was increased to $275 million aggregate principal amount of notes from the previously announced offering size of $250 million aggregate principal amount of notes. Aerie has also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $41.25 million aggregate principal amount of the notes.
- Business Wire
Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it proposes to offer $250 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”), subject to market conditions and other factors. The notes are to be offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Aerie also intends to grant to the initial purchasers of the notes a 13-day option to purchase up to an additional $37.5 million aggregate principal amount of the notes.
- Zacks
Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.
- Simply Wall St.
Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI): Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company...
Motley FoolAerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript
AERI earnings call for the period ending June 30, 2019.
- Zacks
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
Aerie (AERI) delivered earnings and revenue surprises of 8.05% and 8.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know
Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.
- Zacks
Aerie Completes Enrollment Under Rhopressa Study in Japan
Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.
- Zacks
Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
- Business Wire
Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting
Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Jeffrey Calabrese, CPA, as Director of Accounting, reporting to Christopher Staten, Aerie’s Vice President of Finance. Mr. Calabrese will lead external financial reporting, technical accounting and equity accounting. In connection with his acceptance of the position as Director of Accounting, Mr. Calabrese will receive awards totaling 14,400 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date.
- Business Wire
Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences
Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the trea
